FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation

• DOI: 10.1016/j.biopha.2021.112524
• Publication Date: 2021-12-11T17:41:17Z
• Authors: Ai Guo; Kai Li; Hong-Chuan Tian; Bai-Long Tao; Qian Xiao; Dian-Ming Jiang
• Keywords: Osteopontin; Sclerostin

Human fibroblast growth factor 19 (FGF19) has become a potential therapeutic target for metabolic-related diseases. However, the effects of FGF19 on obesity-induced bone loss have not been completely elucidated. The aim this study was to investigate protective in high-fat diet (HFD)-fed obese mice and palmitic acid (PA)-treated osteoblasts further explore its underlying mechanisms. In vivo, we found that alleviated decreased mineral density (BMD) induced by HFD. Micro-CT analysis femur samples histological indicated HFD-induced trabeculae damage trabecular structure. vitro, results suggested ameliorated PA-induced decline osteoblast proliferation, increased cell death impaired morphology. Additionally, protected against activation alkaline phosphatase (ALP) protein expression Collagen-1, Runx-2, osteopontin (OPN) PA. Furthermore, might enhance osteogenic differentiation via Wnt/β-catenin pathway inhibit osteoclastogenesis regulating osteoprotegerin (OPG)/receptor activator NF-κB ligand (RANKL) axis, thus attenuating negative effect PA osteoblasts. conclusion, our promote partially through alleviate loss.